Ultrasound-Guided Alcohol Sclerotherapy to Reduce Pelvic Pain and Improve Quality of Life in Women With Ovarian Endometriomas Aged 18 to 45

What this Trial Is About

Researchers are evaluating whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas. This study compares sclerotherapy to expectant management to determine which approach better helps manage symptoms and quality of life impacts associated with this common form of endometriosis. Participants are randomly assigned to either receive ultrasound-guided alcohol sclerotherapy involving puncture and alcohol treatment of the cysts or to be managed expectantly with standard pain management if needed. The sclerotherapy procedure involves a 15-minute application of absolute ethanol followed by a wash. Both groups will be followed for six months, with assessments at baseline and 6 months post-treatment. During the study, participants will complete quality of life and pain assessments using standardized tools, provide blood and urine samples for biomarker analysis, and undergo ovarian reserve evaluations. Researchers will monitor adverse events, cyst recurrence, fertility outcomes, and healthcare costs. Pregnancy outcomes will be followed for an average of two years. The main outcome is quality of life measured at baseline and 6 months.

Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis